JP2023540806A5 - - Google Patents

Info

Publication number
JP2023540806A5
JP2023540806A5 JP2023516110A JP2023516110A JP2023540806A5 JP 2023540806 A5 JP2023540806 A5 JP 2023540806A5 JP 2023516110 A JP2023516110 A JP 2023516110A JP 2023516110 A JP2023516110 A JP 2023516110A JP 2023540806 A5 JP2023540806 A5 JP 2023540806A5
Authority
JP
Japan
Prior art keywords
delivery vehicle
vehicle according
muscular dystrophy
modulator
indicates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023516110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540806A (ja
JP7875175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049889 external-priority patent/WO2022056277A1/en
Publication of JP2023540806A publication Critical patent/JP2023540806A/ja
Publication of JP2023540806A5 publication Critical patent/JP2023540806A5/ja
Application granted granted Critical
Publication of JP7875175B2 publication Critical patent/JP7875175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023516110A 2020-09-11 2021-09-10 骨格筋への送達プラットフォームおよび使用の方法 Active JP7875175B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063077141P 2020-09-11 2020-09-11
US63/077,141 2020-09-11
US202163214747P 2021-06-24 2021-06-24
US63/214,747 2021-06-24
US202163230381P 2021-08-06 2021-08-06
US63/230,381 2021-08-06
PCT/US2021/049889 WO2022056277A1 (en) 2020-09-11 2021-09-10 Skeletal muscle delivery platforms and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026094898A Division JP2026134779A (ja) 2020-09-11 2026-06-05 骨格筋への送達プラットフォームおよび使用の方法

Publications (3)

Publication Number Publication Date
JP2023540806A JP2023540806A (ja) 2023-09-26
JP2023540806A5 true JP2023540806A5 (cg-RX-API-DMAC7.html) 2024-09-19
JP7875175B2 JP7875175B2 (ja) 2026-06-17

Family

ID=78135129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516110A Active JP7875175B2 (ja) 2020-09-11 2021-09-10 骨格筋への送達プラットフォームおよび使用の方法

Country Status (12)

Country Link
US (1) US20230265429A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210763A1 (cg-RX-API-DMAC7.html)
JP (1) JP7875175B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066588A (cg-RX-API-DMAC7.html)
AU (1) AU2021340710A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189077A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000663A1 (cg-RX-API-DMAC7.html)
IL (1) IL301186A (cg-RX-API-DMAC7.html)
MX (1) MX2023002939A (cg-RX-API-DMAC7.html)
TW (1) TW202218687A (cg-RX-API-DMAC7.html)
UY (1) UY39422A (cg-RX-API-DMAC7.html)
WO (1) WO2022056277A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
US10004814B2 (en) * 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
AU2017354041B2 (en) 2016-11-01 2024-02-01 Arrowhead Pharmaceuticals, Inc. Alpha-V beta-6 integrin ligands and uses thereof
SG11202002967SA (en) 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN120247964A (zh) 2018-02-17 2025-07-04 箭头药业股份有限公司 三炔连接剂和使用方法
CA3098623A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Similar Documents

Publication Publication Date Title
JP7442574B2 (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
ES2929498T3 (es) Conjugados de oligómero de omisión de exones para distrofia muscular
JP2023541404A (ja) DUX4の発現を阻害するためのRNAi剤、その組成物、及び使用方法
JP7291418B2 (ja) Pcsk9を標的としたアンチセンス核酸
JP2017521045A5 (cg-RX-API-DMAC7.html)
TWI924663B (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
JP2019525918A5 (cg-RX-API-DMAC7.html)
JP2022523467A5 (cg-RX-API-DMAC7.html)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2023537798A5 (cg-RX-API-DMAC7.html)
JP2010537640A5 (cg-RX-API-DMAC7.html)
TW202015697A (zh) 用於肌肉萎縮症之外顯子跳躍寡聚物共軛物
JP2022520986A5 (cg-RX-API-DMAC7.html)
TW202426645A (zh) 用於抑制DM1蛋白質激酶(DMPK)表現之RNAi藥劑、其組合物及使用方法
JP2022533358A5 (cg-RX-API-DMAC7.html)
JP6847852B2 (ja) 癌治療のためのヒト抗原R発現のsiRNA阻害
JP2021112197A (ja) ジストロフィー型表皮水疱症を処置するためのアンチセンスオリゴヌクレオチド
JP2023501246A (ja) ベータENaCの発現を阻害するRNAi剤、その組成物および使用方法
JP2023541639A5 (cg-RX-API-DMAC7.html)
JP2017523790A (ja) 代謝障害のためのマイクロrnaの標的化
JP2024051108A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
CN116474107A (zh) 一种缀合物及其中间体化合物和用途
TW202412845A (zh) 用於遞送治療劑至cns組織之脂質結合物
JP2025038098A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマー
CN117187242A (zh) 一种siRNA及其缀合物